

December 27, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUOPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Our letter dated July 7, 2023.

Further to our letter dated July 7, 2023, this is to inform that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company ("CuraTeQ"), has mutually agreed to terminate its agreement with BioFactura Inc, USA relating to BFI-751, the proposed ustekinumab biosimilar product. This decision is aligned with CuraTeQ's strategic portfolio prioritisation and is not expected to have a material impact on the company's overall biosimilars strategy.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as 'Annexure A'.

Please take the above information on record.

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl: a/a

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivi Har, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015

a) name(s) of parties with whom the agreement is entered;	CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company (“ CuraTeQ ”) and BioFactura Inc, USA (“ BioFactura ”)
b) purpose of entering into the agreement	To commercialize BFI-751, a proposed biosimilar to Stelara (Ustekinumab).
c) size of agreement	As per the license agreement, BioFactura would receive license fees spread across different milestones leading to commercialization in regulated markets and CuraTeQ to have global manufacturing rights.
d) shareholding, if any, in the entity with whom the agreement is executed;	Nil
e) significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	<ul style="list-style-type: none"> ➤ A profit-sharing arrangement ➤ Global manufacturing rights ➤ License fee
f) whether the said parties are related to promoter/promoter group/ Group companies in any manner. If yes, nature of relationship;	No
g) whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No
h) in case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable
i) in case of loan agreements, details of lender, nature of the loan, total amount of loan granted, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders for such loan;	Not Applicable
j) any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;	Not Applicable
k) in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):	

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivi Har, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

i. name of parties to the agreement;	CuraTeQ Biologics Private Limited and BioFactura Inc, USA
ii. nature of the agreement;	License Agreement
iii. date of execution of the agreement;	The said agreement was executed on July 7, 2023 and terminated on December 27, 2025.
iv. details of amendment and impact thereof or reasons of termination and impact thereof.	CuraTeQ has mutually agreed to terminate the said agreement with BioFactura and this decision is aligned with CuraTeQ's strategic portfolio prioritisation. This is not expected to have a material impact on the company's overall biosimilars strategy.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivi Har, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com